A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Clinical trial NCT05009329 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05009329
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-26
- Primary completion
- 2026-08-01
- Enrollment
- 315
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.